Julia Z - Search Results

1

Cellular SR-BI and ABCA1-mediated cholesterol efflux are gender-specific in healthy subjects.

Catalano G, Duchene E, Julia Z, Le Goff W, Bruckert E, Chapman MJ, Guerin M. Catalano G, et al. Among authors: julia z. J Lipid Res. 2008 Mar;49(3):635-43. doi: 10.1194/jlr.M700510-JLR200. Epub 2007 Dec 5. J Lipid Res. 2008. PMID: 18057374 Free article.

2

Same-day initiation of bictegravir/emtricitabine/tenofovir alafenamide: Week 48 results of the FAST study-IMEA 055.

Bachelard A, Isernia V, Charpentier C, Benalycherif A, Mora M, Donadille C, Duvivier C, Lacombe K, El Mouhebb M, Spire B, Landman R, Descamps D, Peytavin G, Assoumou L, Ghosn J; FAST study group. Bachelard A, et al. J Antimicrob Chemother. 2023 Mar 2;78(3):769-778. doi: 10.1093/jac/dkad008. J Antimicrob Chemother. 2023. PMID: 36659824

3

Missed opportunities of HIV pre-exposure prophylaxis in France: a retrospective analysis in the French DAT'AIDS cohort.

Lions C, Cabras O, Cotte L, Huleux T, Gagneux-Brugnon A, Makinson A, Cabié A, Bonnet B, Duvivier C, Hocqueloux L, Cua E, Cheret A, Hustache-Mathieu L, Obry-Roguet V, Jacomet C, Poizot-Martin I; DAT’AIDS STUDY GROUP. Lions C, et al. BMC Infect Dis. 2019 Mar 25;19(1):278. doi: 10.1186/s12879-019-3915-5. BMC Infect Dis. 2019. PMID: 30909885 Free PMC article.

4

Avdoralimab (Anti-C5aR1 mAb) Versus Placebo in Patients With Severe COVID-19: Results From a Randomized Controlled Trial (FOR COVID Elimination [FORCE]).

Carvelli J, Meziani F, Dellamonica J, Cordier PY, Allardet-Servent J, Fraisse M, Velly L, Barbar SD, Lehingue S, Guervilly C, Desgrouas M, Camou F, Piperoglou C, Vely F, Demaria O, Karakunnel J, Fares J, Batista L, Rotolo F, Viotti J, Boyer-Chammard A, Lacombe K, Le Dault E, Carles M, Schleinitz N, Vivier E; FOR COVID Elimination (FORCE) Study Group. Carvelli J, et al. Crit Care Med. 2022 Dec 1;50(12):1788-1798. doi: 10.1097/CCM.0000000000005683. Epub 2022 Oct 10. Crit Care Med. 2022. PMID: 36218354 Free PMC article. Clinical Trial.

5

Epidemiological impact of Neisseria gonorrhoeae and Chlamydia trachomatis screening in men having sex with men: a modelling study.

Flaig J, Hocqueloux L, Palich R, Cuzin L, Robineau O, Pugliese P, Delpierre C, Voirin N, Cotte L; Dat'AIDS Study Group. Flaig J, et al. Sex Transm Infect. 2024 Aug 19;100(6):349-355. doi: 10.1136/sextrans-2023-056103. Sex Transm Infect. 2024. PMID: 38789265

6

Substance use and CD4/CD8 ratio in HIV/HCV co-infected people receiving direct-acting antiviral treatment (ANRS CO13 HEPAVIH).

Barré T, Zucman D, Marcellin F, Ramier C, Protopopescu C, Tardieu R, Ory K, Salmon-Céron D, Carrieri P; ANRS CO13 HEPAVIH Study Group. Barré T, et al. J Viral Hepat. 2023 Nov;30(11):897-900. doi: 10.1111/jvh.13865. Epub 2023 Jun 26. J Viral Hepat. 2023. PMID: 37357886 No abstract available.

7

Efficacy and safety of dolutegravir and rilpivirine dual therapy as a simplification strategy: a cohort study.

Gantner P, Cuzin L, Allavena C, Cabie A, Pugliese P, Valantin MA, Bani-Sadr F, Joly V, Ferry T, Poizot-Martin I, Garraffo R, Peytavin G, Fafi-Kremer S, Rey D; Dat'AIDS study group. Gantner P, et al. HIV Med. 2017 Oct;18(9):704-708. doi: 10.1111/hiv.12506. Epub 2017 Apr 26. HIV Med. 2017. PMID: 28444816 Free article. No abstract available.

8

Low-level viral loads and virological failure in the integrase strand transfer era.

Cuzin L, Flandre P, Allavena C, Palich R, Duvivier C, Becker A, Laroche H, Pugliese P, Cabie A; Dat’AIDS Study Group. Cuzin L, et al. J Antimicrob Chemother. 2023 Apr 3;78(4):1111-1116. doi: 10.1093/jac/dkad056. J Antimicrob Chemother. 2023. PMID: 36879512

9

Doravirine plus lamivudine two-drug regimen as maintenance antiretroviral therapy in people living with HIV: a French observational study.

Perfezou P, Hall N, Duthe JC, Abdi B, Seang S, Arvieux C, Lamaury I, Menard A, Marcelin AG, Katlama C, Palich R; Dat’AIDS study group. Perfezou P, et al. J Antimicrob Chemother. 2023 Aug 2;78(8):1929-1933. doi: 10.1093/jac/dkad185. J Antimicrob Chemother. 2023. PMID: 37303236 Free article.

10

Inhibition of CETP by torcetrapib attenuates the atherogenicity of postprandial TG-rich lipoproteins in type IIB hyperlipidemia.

Guerin M, Le Goff W, Duchene E, Julia Z, Nguyen T, Thuren T, Shear CL, Chapman MJ. Guerin M, et al. Among authors: julia z. Arterioscler Thromb Vasc Biol. 2008 Jan;28(1):148-54. doi: 10.1161/ATVBAHA.107.151688. Epub 2007 Oct 19. Arterioscler Thromb Vasc Biol. 2008. PMID: 17951324 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

45 results

Search Page

Filters